Table 4.

Univariate and multivariate Cox analysis of clinicopathological variables in patients with head and neck cancer (n = 98)

	Overall survival				Disease‐free survival
	Univariate		Multivariate		Univariate		Multivariate
	HR (CI 95%)	P‐value	HR (CI 95%)	P‐value	HR (CI 95%)	P‐value	HR (CI 95%)	P‐value
Gender
Female	1 (Reference)	0.459	n.d.	n.d.	1 (Reference)	0.257	n.d.	n.d.
Male	1.23 (0.71–2.13)				1.40 (0.78–2.50)
pT‐stage
T1 + T2	1 (Reference)	0.011	1 (Reference)	0.178	1 (Reference)	0.040	1 (Reference)	0.430
T3 + T4	0.52 (0.32–0.86)		0.65 (0.35–1.22)		0.58 (0.35–0.98)		0.75 (0.37–1.53)
pN‐stage
N0	1 (Reference)	0.020	1 (Reference)	0.012	1 (Reference)	0.011	1 (Reference)	0.025
N1–3	0.57 (0.35–0.92)		0.50 (0.29–0.86)		0.52 (0.32–0.86)		0.53 (0.30–0.92)
p53 IHC staining
<10%	1 (Reference)	0.688	n.d.	n.d.	1 (Reference)	0.273	n.d.	n.d.
≥10%	1.11 (0.68–1.81)				1.33 (0.80–2.22)
GLI IHC staining
<5%	1 (Reference)	0.267	n.d.	n.d.	1 (Reference)	0.324	n.d.	n.d.
≥5%	0.75 (0.46–1.24)				0.77 (0.46–1.29)
SMO IHC staining
<5%	1 (Reference)	0.044	1 (Reference)	0.072	1 (Reference)	0.034	1 (Reference)	0.056
≥5%	0.56 (0.32–0.98)		0.57 (0.30–1.05)		0.53 (0.30–0.95)		0.53(0.28–1.02)
p16 IHC staining
<1%	1 (Reference)	0.021	1 (Reference)	0.001	1 (Reference)	0.028	1 (Reference)	0.002
≥1%	0.55 (0.33–0.91)		0.40 (0.23–0.69)		0.56 (0.33–0.94)		0.41 (0.23–0.72)

All P‐values below a two‐sided alpha of 0.05 have been marked as bold. HR, hazard ratio; CI, confidence interval; n.d., not done in multivariate analysis; IHC, immunohistochemistry; GLI, GLI family zinc finger 1; pT, tumour–node–metastasis (TNM) classification of malignant tumours T stage; pN, TNM classification of malignant tumours N stage; SMO, smoothened, frizzled class receptor.